MIRAE Biobank, Canada

Certification Status: Approved
Registration Status: Completed

Objective: Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in different organs, commonly called immune-related adverse events (irAEs). irAEs can lead to treatment discontinuation, or can be life-threatening in extreme cases. The causes of irAEs are largely unknown and there are no reliable predictive biomarkers. The Montreal Immune-Related Adverse Events (MIRAE) study collects clinical information and biospecimens (blood, tissue, stool) from cancer patients treated with ICI to facilitate research on the identification of predictive biomarkers of irAEs, their causes, and the design of effective management strategies.

Registered Biobank Name MIRAE Biobank
Biobank Leader Dr. Marie Hudson (Director), Manuel Flores Molina (Coordinator)
Country Canada
Email for biobank inquiries manuel.flores.molina.ccomtl@ssss.gouv.qc.ca
Principal Investigator Dr. Marie Hudson, Dr. Wilson Miller, Dr. Khashayar Esfahani, Dr. Sonia del Rincón, Dr. Réjean Lapointe, Dr. Nathalie Johnson
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Oligo - Collection aimed at supporting several research projects, a research group or a research consortium
Biospecimen Collected: